Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Carcinosarcoma

Carcinosarcoma

Carcinosarcoma is a rare, aggressive form of cancer that contains both carcinomatous (epithelial) and sarcomatous (mesenchymal) elements.
It can arise in various organ systems, including the uterus, ovaries, lungs, and other sites.
Carcinosarcomas exhibit a biphasic histology with malignant epithelial and mesenchymal components, and their pathogenesis is not fully understood.
Treatment typically involves a combinaion of surgery, chemotherapy, and radiation therapy, but the prognosis for patients with carcinosarcome is generally poor.
Continued research is needed to better understand the underlying biology of this complex neoplasm and develop more effective therapeutic strategiies.

Most cited protocols related to «Carcinosarcoma»

1
Pan-Cancer Transcriptomic and Proteomic Analysis
Results are based in part upon data generated by TCGA Research Network (http://cancergenome.nih.gov/). We aggregated TCGA transcriptomic and RPPA data from public repositories, listed in the “Data availability” section. RNA-seq expression data were processed by TCGA at the gene level, rather than at the transcript level. Tumors spanned 32 different TCGA projects, each project representing a specific cancer type, listed as follows: LAML, acute myeloid leukemia; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; LGG, lower grade glioma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; CRC, colorectal adenocarcinoma (combining COAD and READ projects); ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THYM, thymoma; THCA, thyroid carcinoma; UCS, uterine carcinosarcoma; UCEC, uterine corpus endometrial carcinoma; UVM, uveal melanoma. Cancer molecular profiling data were generated through informed consent as part of previously published studies and analyzed per each original study’s data use guidelines and restrictions.
Chen F., Chandrashekar D.S., Varambally S, & Creighton C.J. (2019). Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nature Communications, 10, 5679.
Full text: Click here
Publication 2019
4-carboxyphenylglyoxal Adenocarcinoma Adenocarcinoma of Lung Adrenocortical Carcinoma Breast Carcinoma Carcinoma, Thyroid Carcinoma, Transitional Cell Carcinosarcoma Cells Cholangiocarcinoma Chromophobia Chronic Obstructive Airway Disease Diffuse Large B-Cell Lymphoma Endocervix Endometrial Carcinoma Esophageal Cancer Familial Atypical Mole-Malignant Melanoma Syndrome Gene Expression Profiling Genes Glioblastoma Multiforme Glioma Hepatocellular Carcinomas Hypernephroid Carcinomas Kidney Leukemia, Myelocytic, Acute Lung Lymph Malignant Neoplasms Mesothelioma Neck Neoplasms Ovary Pancreas Paraganglioma Pheochromocytoma Prostate Renal Cell Carcinoma RNA-Seq Sarcoma Serous Cystadenocarcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Stomach Testicular Germ Cell Tumor Thymoma Urinary Bladder Uterus Uveal melanoma X-Ray Photoelectron Spectroscopy
2
Comprehensive Pan-cancer RNA-Seq and Protein Expression Analysis
The pancan normalized gene-level RNA-Seq data for the TCGA cohorts were downloaded from the UC Santa Cruz Cancer Genomics Browser [67 (link)] (https://genome-cancer.ucsc.edu/). These cohorts consisted of adrenocortical cancer (ACC, Ntumor = 79, Nnormal 
= 0), bladder urothelial carcinoma (BLCA, Ntumor = 407, Nnormal 
= 19), lower grade glioma (LGG, Ntumor = 530, Nnormal 
= 0), breast invasive carcinoma (BRCA, Ntumor = 1097, Nnormal 
= 113), cervical and endocervical cancer (CESC, Ntumor = 305, Nnormal 
= 3), colon and rectum adenocarcinoma (COADREAD, Ntumor = 383, Nnormal 
= 50), glioblastoma multiforme (GBM, Ntumor = 167, Nnormal 
= 5), head and neck squamous cell carcinoma (HNSC Ntumor = 521, Nnormal 
= 43), kidney chromophobe (KICH, Ntumor = 66, Nnormal 
= 25), kidney clear cell carcinoma (KIRC, Ntumor = 530, Nnormal 
= 72), kidney papillary cell carcinoma (KIRP, Ntumor = 291, Nnormal 
= 32), liver hepatocellular carcinoma (LIHC, Ntumor = 373, Nnormal 
= 50), lung adenocarcinoma (LUAD, Ntumor = 510, Nnormal 
= 58), lung squamous cell carcinoma (LUSC, Ntumor = 502, Nnormal 
= 51), ovarian serous cystadenocarcinoma (OVCA, Ntumor = 266, Nnormal 
= 0), prostate adenocarcinoma (PRAD, Ntumor = 498, Nnormal 
= 52), skin cutaneous melanoma (SKCM, Ntumor = 472, Nnormal 
= 1), thyroid carcinoma (THCA, Ntumor = 513, Nnormal 
= 59), and uterine carcinosarcoma (UCS, Ntumor = 57, Nnormal 
= 0).
TCGA ccRCC-specific analyses were performed with the KIRC datasets downloaded from Firebrowse (http://firebrowse.org). RSEM-normalized gene level data and reverse phase protein array (RPPA) data were used for gene and protein expression analyses, respectively. Samples that had RNA-Seq, mutation and clinical data (n = 415) were included in the discovery phase of the immune infiltration clusters.
The Sato et al. [29 (link)] Agilent microarray gene expression dataset was downloaded from ArrayExpress (http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1980/) and all samples (n = 101) were included in the analysis. The probe identifiers in the Agilent platform were mapped to HGNC gene symbols and the arithmetic mean across identifiers was used for cases where multiple Agilent identifiers mapped to a single HGNC symbol.
The Gerlinger et al. [57 (link)] Affymetrix Human Gene 1.0 ST microarray gene expression dataset was obtained via personal communication with the authors on 10 November 2014. This dataset includes 56 tumor and six normal samples from nine ccRCC patients. All samples were included in our analysis. The probe sets in this Affymetrix platform were mapped to HGNC gene symbols and the geometric mean across probe sets was used for cases where multiple probe sets mapped to a single HGNC symbol.
Şenbabaoğlu Y., Gejman R.S., Winer A.G., Liu M., Van Allen E.M., de Velasco G., Miao D., Ostrovnaya I., Drill E., Luna A., Weinhold N., Lee W., Manley B.J., Khalil D.N., Kaffenberger S.D., Chen Y., Danilova L., Voss M.H., Coleman J.A., Russo P., Reuter V.E., Chan T.A., Cheng E.H., Scheinberg D.A., Li M.O., Choueiri T.K., Hsieh J.J., Sander C, & Hakimi A.A. (2016). Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology, 17, 231.
Full text: Click here
Publication 2016
Adenocarcinoma Adenocarcinoma of Lung Breast Carcinoma Cancer of Adrenal Cortex Carcinoma, Thyroid Carcinoma, Transitional Cell Carcinosarcoma Chromophobia Colon Endocervix Familial Atypical Mole-Malignant Melanoma Syndrome Gene Expression Genes Genome Glioblastoma Multiforme Glioma Hepatocellular Carcinomas Homo sapiens Hypernephroid Carcinomas Kidney Lung Malignant Neoplasms Microarray Analysis Mutation Neck Neoplasms Ovary Patients Prostate Protein Arrays Proteins Rectum RNA-Seq Serous Cystadenocarcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Urinary Bladder Uterus
3
Somatic Copy-Number Profiling of Tumors

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2018
Aneuploidy Carcinosarcoma Chromosomes Copy Number Polymorphism Diploid Cell Endometrial Neoplasms Endometrium Genital Neoplasms, Female Genome Germ Line Malignant Neoplasm of Breast Malignant Neoplasms Mixed Salivary Gland Tumor Neoplasms Ovary Phenobarbital Testicular Germ Cell Tumor Uterine Cervical Neoplasm Uterus
4
Endometrial Cancer Genome-Wide Association Study
The 2695 cases and 2777 controls from the E2C2 consortium were genotyped using the Illumina Human OmniExpress array (2271 cases, 2219 controls from the United States) or the Illumina Human 660W array (424 cases, 558 controls from Poland)33 (link) and both sets were separately imputed to the 1000 Genomes Project v3 reference panel using “minimac2” software, following standard quality control steps38 (link),39 (link).
The 288 cases from six population-based case–control studies within the Women’s Health Initiative were genotyped using five different arrays (Supplementary Data 1) and were each separately imputed using the combined 1000 Genome Project v3 and UK10K reference panels using “minimac2” software39 (link), following standard quality measures and the exclusion of SNPs with a MAF <1%. Five controls for each case were selected randomly, matched on study.
Data were also included from the first phase of UK Biobank genotyping, comprising 636 Cancer Registry-confirmed endometrial cancer cases (as of October 2016) and 62,853 cancer-free female controls. Samples were genotyped using Affymetrix UK BiLEVE Axiom array and Affymetrix UK Biobank Axiom® array and imputed to the combined 1000 Genome Project v3 and UK10K reference panels using SHAPEIT340 (link) and IMPUTE341 .
No analyses to identify duplicates or relatives between samples from the E2C2, WHI, or UK Biobank studies, and any other study were carried out. However, given the sampling frame of these studies, it is very unlikely that there would have been any meaningful sample overlap.
After QC exclusions, the analysis included 12,906 endometrial cancer cases (3613 of which have not been included in any previous publication) and 108,979 controls. Analyses were also carried out specifically for endometrial cancer of endometrioid histology (8758 cases) and endometrial cancer with non-endometrioid histology (1230 cases). Exploratory analyses for specific non-endometrioid histologies (serous carcinoma, carcinosarcoma, clear cell carcinoma, and mucinous carcinoma) included a small number of cases of mixed histotype, where the major component was non-endometrioid. The UK Biobank data did not include information about histology.
All participating studies were approved by research ethics committees from QIMR Berghofer Medical Research Institute, University-Clinic Erlangen, Karolinska Institutet, UZ Leuven, The Mayo Clinic, The Hunter New England Health District, The Regional Committees for Medical and Health Research Ethics Norway, and the UK National Research Ethics Service (04/Q0803/148 and 05/MRE05/1). All participants provided written, informed consent.
O’Mara T.A., Glubb D.M., Amant F., Annibali D., Ashton K., Attia J., Auer P.L., Beckmann M.W., Black A., Bolla M.K., Brauch H., Brenner H., Brinton L., Buchanan D.D., Burwinkel B., Chang-Claude J., Chanock S.J., Chen C., Chen M.M., Cheng T.H., Clarke C.L., Clendenning M., Cook L.S., Couch F.J., Cox A., Crous-Bous M., Czene K., Day F., Dennis J., Depreeuw J., Doherty J.A., Dörk T., Dowdy S.C., Dürst M., Ekici A.B., Fasching P.A., Fridley B.L., Friedenreich C.M., Fritschi L., Fung J., García-Closas M., Gaudet M.M., Giles G.G., Goode E.L., Gorman M., Haiman C.A., Hall P., Hankison S.E., Healey C.S., Hein A., Hillemanns P., Hodgson S., Hoivik E.A., Holliday E.G., Hopper J.L., Hunter D.J., Jones A., Krakstad C., Kristensen V.N., Lambrechts D., Marchand L.L., Liang X., Lindblom A., Lissowska J., Long J., Lu L., Magliocco A.M., Martin L., McEvoy M., Meindl A., Michailidou K., Milne R.L., Mints M., Montgomery G.W., Nassir R., Olsson H., Orlow I., Otton G., Palles C., Perry J.R., Peto J., Pooler L., Prescott J., Proietto T., Rebbeck T.R., Risch H.A., Rogers P.A., Rübner M., Runnebaum I., Sacerdote C., Sarto G.E., Schumacher F., Scott R.J., Setiawan V.W., Shah M., Sheng X., Shu X.O., Southey M.C., Swerdlow A.J., Tham E., Trovik J., Turman C., Tyrer J.P., Vachon C., VanDen Berg D., Vanderstichele A., Wang Z., Webb P.M., Wentzensen N., Werner H.M., Winham S.J., Wolk A., Xia L., Xiang Y.B., Yang H.P., Yu H., Zheng W., Pharoah P.D., Dunning A.M., Kraft P., De Vivo I., Tomlinson I., Easton D.F., Spurdle A.B, & Thompson D.J. (2018). Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 9, 3166.
Full text: Click here
Publication 2018
Adenocarcinoma, Clear Cell Carcinosarcoma Endometrial Carcinoma Endometrium Ethics Committees, Research Genome Homo sapiens Malignant Neoplasms Mucinous Adenocarcinoma Reading Frames Serous Cystadenocarcinoma Single Nucleotide Polymorphism Woman
5
Establishment and Characterization of Ovarian Cancer Cell Lines
The OCI cell lines and OCMI medium are available from the Live Tumor Culture Core (LTCC) at Sylvester Comprehensive Cancer Center (SCCC), Miller School of Medicine, University of Miami http://sylvester.org/shared-resources/Live-Tumor-Culture-Core In order to establish the cell lines, fresh tumor tissue fragments are minced and plated on Primaria (BD Biosciences) plates before and after digestion with 1 mg/ml collagenase (Roche). The tumor cells are cultured in nutrient medium described previously 16 (link), supplemented with insulin, hydrocortisone, EGF, cholera toxin, and serum as described in Supplementary Methods. We refer to this version of the medium as Ovarian Carcinoma Modified Ince medium (OCMI). This formulation is supplemented with 17β-estradiol for endometrioid and mucinous tumors (OCMIe). The papillary serous, clear cell, dysgerminoma, and carcinosarcoma tumors are initially cultured in 5% CO2 and regular O2 at 37 C as monolayers attached to Primaria culture plates. The endometrioid and mucinous tumors are initially cultured in 5% CO2 and low O2 (5%) at 37 C as monolayers attached to Primaria culture plates. Adjustments in O2 and plates are made for individual cell lines as necessary (Supplementary Table 3). The tumor cells are passaged at a ~ 1:3 ratio once a week and plated into a new flask at approximately 1×104 cells/cm2. During the initial weeks of culture, (~1–5) the plates are treated with diluted trypsin first, in order to deplete stromal cells. The remaining cells that are still attached to the culture plate are treated with 0.25% trypsin for sub-culturing. In general, tumor cultures are free of stromal and normal cell types within 4–6 passages. The SOC cell lines were STR validated and cultured as per the instructions of the vendor. OCI lines will be available from the Ince laboratory upon publication. All study procedures were approved by the Institutional Review Boards of the University of Miami, Brigham & Women’s and Massachusetts General Hospitals to collect discarded tissues with written consent from all patients. See Supplementary Note 1 for further details of culture methods.
Ince T.A., Sousa A.D., Jones M.A., Harrell J.C., Agoston E.S., Krohn M., Selfors L.M., Liu W., Chen K., Yong M., Buchwald P., Wang B., Hale K.S., Cohick E., Sergent P., Witt A., Kozhekbaeva Z., Gao S., Agoston A.T., Merritt M.A., Foster R., Rueda B.R., Crum C.P., Brugge J.S, & Mills G.B. (2015). Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nature Communications, 6, 7419.
Publication 2015
Carcinosarcoma Cell Lines Cells Cholera Toxin Collagenase Culture Techniques Digestion Dysgerminoma Endometrium Estradiol Ethics Committees, Research Hydrocortisone Insulin Malignant Neoplasms Neoplasms Neoplasms, Mucinous Nutrients Ovarian Cancer Patients Serum Stromal Cells Tissues Trypsin Woman

Most recents protocols related to «Carcinosarcoma»

1
Adjuvant Therapy for Residual Endometrial Cancer
1. Patients with residual tumors, whether measurable or non-measurable after surgery
2. Endometrioid adenocarcinoma combined with other histological types
3. Non-endometrial carcinoma, for example, serous carcinoma, clear cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, or uterine sarcoma (including carcinosarcoma)
4. An interval between the operation and the start of adjuvant therapy exceeding 8 weeks
5. Previous pelvic radiotherapy
6. Previous history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 5 years
7. History of myocardial infarction, stroke, unstable angina, decompensated heart failure, or deep vein thrombosis
8. Impaired renal or cardiac function.
9. Known intolerance to intervention therapy or any excipients
10. Known psychiatric or substance abuse disorders that would interfere with the participant's ability to cooperate with the requirements of the study.
Li Y., Zhu C., Xie H., Chen Y., Lv W., Xie X, & Wang X. (2023). Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). Journal of Gynecologic Oncology, 34(2), e37.
Publication 2023
Adenocarcinoma, Clear Cell Adenocarcinoma, Endometrioid Angina, Unstable Carcinoma, Neuroendocrine Carcinosarcoma Cerebrovascular Accident Congestive Heart Failure Endometrial Carcinoma Heart Kidney Malignant Neoplasms Myocardial Infarction Neoplasms, Second Primary Patients Pelvis Pharmaceutical Adjuvants Residual Tumor Sarcoma Serous Cystadenocarcinoma Substance Abuse Therapeutics Undifferentiated Carcinoma Uterus Veins
2
TCGA pan-cancer gene expression profiling
Manifests containing fragments per kilobase per million (FPKM) normalized RNA-seq data from 34 TCGA cohorts – Acute Myeloid Leukemia - (TCGA-LAML), Adrenocortical carcinoma (TCGA-ACC), Bladder Urothelial Carcinoma (TCGA-BLCA), Glioblastoma multiforme and Brain Lower Grade Glioma and (TCGA-GBMLGG), Breast Invasive Carcinomas (TCGA-BRCA), Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA-CESC), Cholangiocarcinoma (TCGA-CHOL), Chronic Myelogenous Leukemia (TCGA-LCML), Colon Adenocarcinoma (TCGA-COAD), Esophageal Carcinoma (TCGA-ESCA), Head and Neck Squamous Cell Carcinoma (TCGA-HNSC), pan-Kidney Cancer (TCGA-KIPAN), Liver Hepatocellular Carcinoma (TCGA-LIHC), Lung Adenocarcinoma (TCGA-LUAD), Lung Squamous Cell Carcinoma (TCGA-LUSC), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA-DLBC), Mesothelioma (TCGA-MESO), Ovarian Serous Cystadenocarcinoma (TCGA-OV), Pancreatic Adenocarcinoma (TCGA-PAAD), Pheochromocytoma and Paraganglioma (TCGA-PCPG), Prostate Adenocarcinoma (TCGA-PRAD), Rectum Adenocarcinoma (TCGA-READ), Sarcoma (TCGA-SARC), Skin Cutaneous Melanoma (TCGA-SKCM), Stomach Adenocarcinoma (TCGA-STAD), Testicular Germ Cell Tumors (TCGA-TGCT), Thymoma (TCGA-TGCT), Thyroid Carcinoma (TCGA-THCA), Uterine Carcinosarcoma (TCGA-USC), Uterine Corpus Endometrial Carcinoma (TCGA-UCES), Uveal Melanoma (TCGA-UVM) were downloaded from the Broad Institute GDAC (TCGA data version 20150601). Patients were then sorted by increasing B7-H3 expression in each cohort.
Liu H.J., Du H., Khabibullin D., Zarei M., Wei K., Freeman G.J., Kwiatkowski D.J, & Henske E.P. (2023). mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion. Nature Communications, 14, 1214.
Full text: Click here
Publication 2023
4-carboxyphenylglyoxal Adenocarcinoma Adenocarcinoma of Lung Adrenocortical Carcinoma Brain Breast Carcinoma Cancer of Kidney Carcinoma, Thyroid Carcinoma, Transitional Cell Carcinosarcoma Cholangiocarcinoma Chronic Obstructive Airway Disease Colon Adenocarcinomas Diffuse Large B-Cell Lymphoma Endocervix Endometrial Carcinoma Esophageal Cancer Familial Atypical Mole-Malignant Melanoma Syndrome Glioblastoma Multiforme Glioma Hepatocellular Carcinomas Leukemia, Myelocytic, Acute Leukemias, Chronic Granulocytic Lung Lymph Mesothelioma Neck Neoplasms Ovary Pancreas Paraganglioma Patients Pheochromocytoma Prostate Rectum RNA-Seq Sarcoma Serous Cystadenocarcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Stomach Testicular Germ Cell Tumor Thymoma Urinary Bladder Uterus Uveal melanoma X-Ray Photoelectron Spectroscopy
3
Comprehensive Transcriptomic Analysis of 33 Cancer Types
The TCGA Research Network (https://portal.gdc.cancer.gov/) has analyzed clinical and molecular data from over 10,000 oncology patients in 33 countries, covering 33 different tumor types and over 10,000 oncology patients. Transcriptomic RNA-seq data for 33 cancers were extracted from TCGA database. 33 cancer types were included: adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B cell lymphoma (DLBC), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), pheochromocytoma and paraganglioma (PCPG), rectum adenocarcinoma (READ), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), cholangiocarcinoma (CHOL), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), mesothelioma (MESO), sarcoma (SARC), uveal melanoma (UVM), and uterine carcinosarcoma (UCS).
Zhu J., Zheng J., Zhang J., Wang S., Wang L, & Zhao Y. (2023). A Comprehensive and Systematic Analysis Revealed the Role of ADAR1 in Pan-Cancer Prognosis and Immune Implications. Disease Markers, 2023, 7620181.
Full text: Click here
Publication 2023
Adenocarcinoma Adenocarcinoma of Lung Adrenocortical Carcinoma Brain Breast Carcinoma Carcinoma, Thyroid Carcinoma, Transitional Cell Carcinosarcoma Cells Cholangiocarcinoma Chromophobia Colon Adenocarcinomas Diffuse Large B-Cell Lymphoma Endocervix Endometrial Carcinoma Esophageal Cancer Familial Atypical Mole-Malignant Melanoma Syndrome Gene Expression Profiling Glioblastoma Multiforme Glioma Hepatocellular Carcinomas Hypernephroid Carcinomas Kidney Leukemia, Myelocytic, Acute Lung Lymph Malignant Neoplasms Mesothelioma Neck Neoplasms Ovary Pancreas Paraganglioma Patients Pheochromocytoma Prostate Rectum Renal Cell Carcinoma RNA-Seq Sarcoma Serous Cystadenocarcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Stomach Testicular Germ Cell Tumor Thymoma Urinary Bladder Uterus Uveal melanoma
4
Comprehensive Analysis of JUN Expression across Human Cancers
We used the Gene Expression Profiling Interactive Analysis (GEPIA2) [76 (link)] to determine JUN expression in various human cancers, including in brain tumors. Transcripts per million (TPM) values were extracted from different TCGA and Genotype-Tissue Expression (GTEx) datasets, and median gene expression in each cancer and paired normal tissues was calculated and used as an input to R. The following cancers and corresponding healthy tissues were examined: Adrenocortical carcinoma (ACC) and Adrenal Gland; Bladder Urothelial Carcinoma (BCLA) and bladder; Breast invasive carcinoma (BRCA) and breast; Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) and cervix uteri; Colon adenocarcinoma (COAD) and colon; Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC) and blood, Esophageal carcinoma (ESCA) and esophagus; Glioblastoma multiforme (GBM) and brain; Kidney Chromophobe (KICH) and kidney; Kidney renal clear cell carcinoma (KIRC) and kidney; Kidney renal papillary cell carcinoma (KIRP) and kidney; Acute Myeloid Leukemia (LAML) and bone marrow; Brain Lower Grade Glioma (LGG) and brain; Liver hepatocellular carcinoma (LIHC) and liver; Lung adenocarcinoma (LUAD) and lung; Lung squamous cell carcinoma (LUSC) and lung; Ovarian serous cystadenocarcinoma (OV) and ovary; Pancreatic adenocarcinoma (PAAD) and pancreas; Prostate adenocarcinoma (PRAD) Prostate, Rectum adenocarcinoma (READ) and colon; Skin Cutaneous Melanoma (SKCM) and skin; Stomach adenocarcinoma (STAD) and stomach; Testicular Germ Cell Tumors (TGCT) and testis; Thyroid carcinoma (THCA) and thyroid; Thymoma (THYM) and blood; Uterine Corpus Endometrial Carcinoma (UCEC) and uterus; Uterine Carcinosarcoma (UCS) and uterus. The JUN mRNA expression profile was compared between tumor samples (TCGA) and paired normal tissues (TCGA normal + GTEx normal), and statistical significance was determined using one-way ANOVA and disease state (Tumor versus healthy tissue of tumor origin).
Roura A.J., Szadkowska P., Poleszak K., Dabrowski M.J., Ellert-Miklaszewska A., Wojnicki K., Ciechomska I.A., Stepniak K., Kaminska B, & Wojtas B. (2023). Regulatory networks driving expression of genes critical for glioblastoma are controlled by the transcription factor c-Jun and the pre-existing epigenetic modifications. Clinical Epigenetics, 15, 29.
Full text: Click here
Publication 2023
Adenocarcinoma Adenocarcinoma of Lung Adrenal Glands Adrenocortical Carcinoma BLOOD Bone Marrow Brain Brain Neoplasms Breast Breast Carcinoma Carcinoma, Thyroid Carcinoma, Transitional Cell Carcinosarcoma Cells Cervix Uteri Chromophobia Colon Colon Adenocarcinomas Diffuse Large B-Cell Lymphoma Endocervix Endometrial Carcinoma Esophageal Cancer Esophagus Familial Atypical Mole-Malignant Melanoma Syndrome Gene Expression Profiling Genes, Neoplasm Genotype Glioblastoma Multiforme Glioma Hepatocellular Carcinomas Homo sapiens Hypernephroid Carcinomas Kidney Leukemia, Myelocytic, Acute Liver Lung Lymph Malignant Neoplasms Neck Neoplasms neuro-oncological ventral antigen 2, human Oncogenes Ovary Pancreas Prostate Rectum Renal Cell Carcinoma RNA, Messenger Serous Cystadenocarcinoma Skin Squamous Cell Carcinoma Stomach Testicular Germ Cell Tumor Testis Thymoma Thyroid Gland Tissues Urinary Bladder Uterus
5
Retrospective Study of High-Risk Endometrial Cancer

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Abdomen Adenocarcinoma, Clear Cell Aftercare amant Aorta Carcinoma, Papillary Carcinosarcoma Chest Combination Drug Therapy Diagnosis Endometrial Carcinoma Endometrial Neoplasms Ethics Committees, Research Hysterectomy Laparoscopy Laparotomy Lymph Node Excision Neoplasms, Multiple Primary Operative Surgical Procedures Patients Pelvic Examination Pelvis Pharmaceutical Adjuvants Pharmacotherapy Platinum Radiography, Thoracic Radiotherapy Recurrence Relapse Sentinel Lymph Node Serum Surgeons taxane Therapeutics Uterus Woman X-Ray Computed Tomography Zonal

Top products related to «Carcinosarcoma»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Cellquest software by BD
Sourced in United States, Germany, United Kingdom, Italy, Canada, China, Japan, Belgium, France, Spain, Switzerland, Poland, Uruguay, Denmark, Singapore
CellQuest software is a data acquisition and analysis software designed for flow cytometry applications. It provides tools for acquiring, processing, and analyzing flow cytometry data.
3
Jetprime by Polyplus Transfection
Sourced in France, United States, China, United Kingdom, Germany
JetPRIME is a transfection reagent that facilitates the delivery of nucleic acids, such as plasmid DNA, siRNA, and mRNA, into a variety of mammalian cell lines. It is designed to enhance transfection efficiency while maintaining high cell viability.
4
Hm450 array by Illumina
Sourced in Canada, United States
The HM450 array is a microarray platform developed by Illumina for the analysis of DNA methylation patterns. The core function of the HM450 array is to measure the methylation status of over 450,000 CpG sites across the human genome.
5
Cell line 96 well nucleofector kit sf by Lonza
Sourced in France
The Cell Line 96-well Nucleofector Kit SF is a laboratory equipment designed for the transfection of various cell types. It is a 96-well format kit that utilizes the Nucleofector technology to facilitate the efficient delivery of nucleic acids, such as plasmids, into cells. The kit provides the necessary buffers and reagents to perform the Nucleofection process.
6
Cell line nucleofector kit 5 by Lonza
Sourced in Germany, Switzerland, United States, United Kingdom
The Cell Line Nucleofector Kit V is a laboratory product designed for the transfection of various cell types. It facilitates the introduction of nucleic acids, such as DNA or RNA, into cells using an electroporation-based technology. The kit provides the necessary reagents and protocols for efficient and consistent cell transfection.
7
Glutamine by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, France, Italy, China, Australia, Austria, Switzerland, Canada, Israel, Belgium, Spain, Japan, Macao, Netherlands, Ireland, Poland, New Zealand, Gabon
Glutamine is a naturally occurring amino acid that plays a crucial role in various metabolic processes. It serves as a primary fuel source for rapidly dividing cells, such as those found in the intestines and immune system. Glutamine is also involved in the synthesis of other amino acids, proteins, and nucleic acids. As a laboratory reagent, it is commonly used in cell culture media to support the growth and proliferation of cells.
8
Methylationepic beadchip microarray by Illumina
Sourced in United States
The Illumina MethylationEPIC BeadChip microarray is a high-throughput platform designed for comprehensive analysis of DNA methylation. The microarray interrogates over 850,000 methylation sites across the human genome, covering 99% of RefSeq genes, with an emphasis on CpG islands, shores, and shelves. The MethylationEPIC BeadChip provides a cost-effective solution for large-scale epigenomic studies.
9
Allprep dna rna ffpe kit by Qiagen
Sourced in Germany, United States, Netherlands, Sweden, United Kingdom, Canada, Spain
The AllPrep DNA/RNA FFPE Kit is a laboratory product designed to extract and purify both DNA and RNA from formalin-fixed, paraffin-embedded (FFPE) samples. The kit provides a standardized protocol for simultaneous isolation of genomic DNA and total RNA from the same FFPE tissue sample.
10
Penicillin streptomycin by Lonza
Sourced in United States, Switzerland, Belgium, United Kingdom, Germany, Italy, France, Spain, Netherlands, Australia, Canada, Austria, Sweden, Gabon, New Zealand
Penicillin/streptomycin is a solution containing two antibiotics commonly used in cell culture and molecular biology applications. The solution provides a way to prevent bacterial contamination in laboratory settings.

More about "Carcinosarcoma"

Carcinosarcoma is a rare and aggressive form of cancer that contains both carcinoma (epithelial) and sarcoma (mesenchymal) components.
This biphasic neoplasm can arise in various organs, including the uterus, ovaries, lungs, and other sites.
The pathogenesis of carcinosarcoma is not fully understood, but it is believed to involve complex genetic and molecular alterations.
Researchers studying carcinosarcoma may utilize a variety of tools and techniques to enhance their research.
For example, the PubCompare.ai platform can help locate the best protocols from literature, preprints, and patents, providing AI-driven comparisons to maximize reproducibility and accuracy.
Additionally, techniques like FBS (Fetal Bovine Serum) culture, CellQuest software analysis, JetPRIME transfection, HM450 array methylation profiling, Cell Line 96-well Nucleofector Kit SF and Cell Line Nucleofector Kit V for cell line manipulation, Glutamine supplementation, MethylationEPIC BeadChip microarray, AllPrep DNA/RNA FFPE Kit for nucleic acid extraction, and Penicillin/streptomycin for cell culture can be employed to support carcinosarcoma research.
Despite advances in treatment, which typically involves a combinatioin of surgery, chemotherapy, and radiation therapy, the prognosis for patients with carcinosarcoma remains generally poor.
Continued research is needed to better understand the underlying biology of this complex neoplasm and develop more effective therapeutic strategies to improve patient outcomes.